(Q41104419)

English

Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II

scientific article published on June 15, 1997

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II (English)

1 reference

10.1016/S0006-2952(97)00013-0

https://api.crossref.org/works/10.1016/S0006-2952(97)00013-0

11 November 2024

author name string

B. B. Hasinoff

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9256159

11 November 2024

T. I. Kuschak

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9256159

11 November 2024

A. M. Creighton

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9256159

11 November 2024

C. L. Fattman

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9256159

11 November 2024

W. P. Allan

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9256159

11 November 2024

P. Thampatty

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9256159

11 November 2024

J. C. Yalowich

7

0000-0001-5414-573X

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9256159

11 November 2024

language of work or name

0 references

publication date

1 June 1997

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

15 June 1997

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9256159

11 November 2024

full work available at URL

https://api.elsevier.com/content/article/PII:S0006295297000130?httpAccept=text/xml

1 reference

10.1016/S0006-2952(97)00013-0

https://api.crossref.org/works/10.1016/S0006-2952(97)00013-0

11 November 2024

https://api.elsevier.com/content/article/PII:S0006295297000130?httpAccept=text/plain

1 reference

10.1016/S0006-2952(97)00013-0

https://api.crossref.org/works/10.1016/S0006-2952(97)00013-0

11 November 2024

Biochemical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

53

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

1843-1853

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane).

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900013-0

7 January 2021

Phase II study: treatment of non-Hodgkin's lymphoma with an oral antitumor derivative of bis(2,6-dioxopiperazine)

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900013-0

7 January 2021

Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16)

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900013-0

7 January 2021

Antitumour Activity in a Series of bisDiketopiperazines

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900013-0

7 January 2021

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900013-0

7 January 2021

Pharmacodynamics of the hydrolysis-activation of the cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900013-0

7 January 2021

The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900013-0

7 January 2021

When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900013-0

7 January 2021

Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16)-resistant human leukemia K562 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900013-0

7 January 2021

The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900013-0

7 January 2021

Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900013-0

7 January 2021

Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900013-0

7 January 2021

A quantitative decatenation assay for type II topoisomerases

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900013-0

7 January 2021

Metal binding by pharmaceuticals. Part 2. Interactions of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II) and Zn(II) with the intracellular hydrolysis products of the antitumour agent ICRF 159 and its inactive homologue ICRF 192

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900013-0

7 January 2021

Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900013-0

7 January 2021

Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900013-0

7 January 2021

Topoisomerase Poisons: Harnessing the Dark Side of Enzyme Mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900013-0

7 January 2021

Activity of DMP 840, a new bis-naphthalimide, on primary human tumor colony-forming units.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900013-0

7 January 2021

The capture of a DNA double helix by an ATP-dependent protein clamp: a key step in DNA transport by type II DNA topoisomerases

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900013-0

7 January 2021

Multidrug resistance mediated by the multidrug resistance protein (MRP) gene.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2897%2900013-0

7 January 2021

Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors

1

1 reference

10.1016/S0006-2952(97)00013-0

https://api.crossref.org/works/10.1016/S0006-2952(97)00013-0

11 November 2024

Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp

4

1 reference

10.1016/S0006-2952(97)00013-0

https://api.crossref.org/works/10.1016/S0006-2952(97)00013-0

11 November 2024

Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells

11

1 reference

10.1016/S0006-2952(97)00013-0

https://api.crossref.org/works/10.1016/S0006-2952(97)00013-0

11 November 2024

In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone

12

1 reference

10.1016/S0006-2952(97)00013-0

https://api.crossref.org/works/10.1016/S0006-2952(97)00013-0

11 November 2024

Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives

23

1 reference

10.1016/S0006-2952(97)00013-0

https://api.crossref.org/works/10.1016/S0006-2952(97)00013-0

11 November 2024

Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A

30

1 reference

10.1016/S0006-2952(97)00013-0

https://api.crossref.org/works/10.1016/S0006-2952(97)00013-0

11 November 2024

DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines

40

1 reference

10.1016/S0006-2952(97)00013-0

https://api.crossref.org/works/10.1016/S0006-2952(97)00013-0

11 November 2024

Resistance to etoposide in human leukemia HL-60 cells: reduction in drug-induced DNA cleavage associated with hypophosphorylation of topoisomerase II phosphopeptides

41

1 reference

10.1016/S0006-2952(97)00013-0

https://api.crossref.org/works/10.1016/S0006-2952(97)00013-0

11 November 2024

Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells

42

1 reference

10.1016/S0006-2952(97)00013-0

https://api.crossref.org/works/10.1016/S0006-2952(97)00013-0

11 November 2024

Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells

43

1 reference

10.1016/S0006-2952(97)00013-0

https://api.crossref.org/works/10.1016/S0006-2952(97)00013-0

11 November 2024

Identifiers

10.1016/S0006-2952(97)00013-0

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41104419&oldid=2273154801"